Mass Spectrometry In-Depth Focus 2017
In this Mass Spectrometry In-Depth Focus: Mass spectrometry in the development of protein biologics; and GC-MS applications in pharmaceuticals analysis...
List view / Grid view
Articles
Microbiology In-Depth Focus 2017
In this Microbiology In-Depth Focus: Endotoxin masking hold-time study performance parameters; Microbiological monitoring pharmaceutical water systems; The rush to rapid microbiological methods - or not; and an expert view with Charles River Laboratories...
Why combatting cybercrime is critical for life science companies
Biotech and pharmaceutical firms hold vast amounts of valuable data and information making them prime targets for cyber-attacks – so how are they protecting themselves?
Single-use systems for biotechnology products
Single-use systems have become an important tool in the development and scale up of biotechnology processes. Single-use systems save space, increase flexibility in scale and space planning and, to a large extent, eliminate cleaning costs in development and change over.
Packaging In-Depth Focus 2017
FMD and supply chain security; Strategic aspects of change control for pharmaceutical packaging systems; and does the Falsified Medicines Directive lead to a European pack coding guideline?
2017 Pipelines: Drugs to watch
The annual Drugs to Watch report forecasts that eight new drugs will enter the market in 2017 and achieve blockbuster sales of more than $900 billion by 2021...
Improving healthcare professional engagement: Why quality customer data is key
10 April 2017 | By Guillaume Roussel, Director of Strategy, Veeva OpenData, Europe, Veeva Systems
Veeva's Guillaume Roussel explains how customer data can create personalised multichannel communication with healthcare professionals in the industry...
Alliance management organisational development: A Bayer perspective
4 April 2017 | By Christoph Huwe, Strategic Alliance Manager Therapeutics at Bayer Pharmaceuticals, Global External Innovation & Alliances
Ahead of the 7th Annual Strategic Alliance Management for Pharma conference, we spoke with Bayer's Christoph Huwe about the organisational development of alliance management...
2017 pipelines: Analysing future trends in the $12billion diabetes market
3 April 2017 | By Dr David Pugh, IDTechEx
The latest 2017 pipelines explores new emerging methods of glucose monitoring, analysing these technologies in the new report from IDTechEx Research...
Serialisation reconciliation: a blind spot in your finished product’s manufacturing compliance?
30 March 2017 | By Pasi Kemppainen, Executive Consultant, Pharma Serialisation and Traceability
Pharma serialisation expert, Pasi Kemppainen, gives us his insights on how serialisation reconciliation can ensure product integrity and patient safety...
How Panacea is paving the way for vaccine immunotherapies
29 March 2017 | By Niamh Marriott, Junior Editor
We caught up with the CEO & CSO of Panacea for the latest on vaccine immunotherapies - "As a scientist, as long as you are observant and persistent, you may come up with breakthrough discoveries"
Redefining Pharma’s relationship with healthcare
28 March 2017 | By Robert Groebel, Vice President of global medical strategy, Veeva
Veeva's Robert Groebel lays out the best practices toward a more coordinated, better healthcare stakeholder experience...
Seal of approval: What makes a seal safe, hygienic and cost-effective?
22 March 2017 | By Russ Pimblett, Business Development Manager (Food, Pharmaceutical and Biomedical), FTL
FTL's Russ Pimblett talks us through sealing issues: colour options, materials choices, hygiene concerns and how to be cost effective and safe...
Lipid-based formulations: Their advantages in early development
21 March 2017 | By Kaspar van den Dries PhD, Senior Director and Principal Scientist, Solid Dose Development, Patheon
Patheon's Kaspar van den Dries shows the advantages of considering lipid formulation in early development to optimise a molecule’s developability...
Gilead on HIV: New research, new treatments and the potential for a cure
15 March 2017 | By Mike Elliott, Vice President, Medical Affairs, Gilead Sciences
We caught up with Gilead’s Mike Elliott to find out the latest in HIV medication and whether a cure is finally within our reach…
